Roxana Moayedifar

Dr. Roxana Moayedifar

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 December 2023 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Open access
RMRoxana Moayedifar
Roxana Moayedifar
YSYasuhiro Shudo
Yasuhiro Shudo
MKMasashi Kawabori
Masashi Kawabori
SSScott Silvestry
Scott Silvestry
JSJacob Schroder
Jacob Schroder
AZAndreas Zuckermann
Andreas Zuckermann
The prevalence of end stage heart failure and patients that could benefit from heart transplantation requires an expansion of the donor pool, relying on the transplant community to continually re-evaluate and expand the use of extended criteria donor organs. Introduction of new technologies such as the Paragonix SherpaPak Cardiac Transport System aids in this shift. We seek to analyze the impact of the SherpaPak system on recipient outcomes who receive extended criteria organs in the GUARDIAN Heart Registry. Between October 2015-December 2022, 1,113 adults from 15 US centers receiving donor hearts utilizing either SherpaPak (N=560) or conventional ice storage (Ice, N=453) were analyzed from the GUARDIAN-Heart registry using summary statistics. A previously published set of criteria was used to identify extended criteria donors, which included 193 SherpaPak and 137 ice. There were a few baseline differences among recipients in the 2 cohorts, most notably IMPACT Scores, distance traveled and total ischemic time were significantly greater in SherpaPak, and significantly more donor hearts in the SherpaPak cohort had >4 hours total ischemia time. Post-transplant MCS utilization (SherpaPak 22.3% vs. ice 35.0%, p=0.012) and new ECMO/VAD (SherpaPak 7.8% vs. ice 15.3%, p=0.033) was significantly reduced, and the rate of severe PGD (SherpaPak 6.2% vs. ice 13.9%, p=0.022) was significantly reduced by over 50% in hearts preserved using SherpaPak. One-year survival between cohorts was similar (SherpaPak 92.9% vs. ice 89.6%, p=0.27). This subgroup analysis demonstrates that SherpaPak can be safely used to utilize extended criteria donors, with low severe PGD rates.

30 May 2025 in ASAIO Journal
Verified
Journal Article
Open access
GWGregor Widhalm
Gregor Widhalm
TATheodor Abart
Theodor Abart
KEKatharina Ebenberger
Katharina Ebenberger
ABAngelika Berger
Angelika Berger
RMRoxana Moayedifar
Roxana Moayedifar
Thomas SchlöglhoferThomas Schlöglhofer
Thomas Schlöglhofer
Left ventricular assist devices (LVADs) improve outcomes but often compromise quality of life (QoL) due to usability issues with wearables. This study compared the usability of CorWave LVAD (CW) peripherals prototypes to HeartMate 3 LVAD (HM3) peripherals through a cross-sectional, simulation-based approach involving LVAD-naive laypeople, and heart transplantation (HTX) patients post-LVAD support. Simulations encompassed six tasks, measuring initial success rates, duration to success, pump-off time, and a post-scenario survey. Forty-six untrained participants (16 CW vs. 30 HM3; 12.5% vs. 20% female, p = 0.69; 56.2% vs. 50.0% HTX patients, p = 0.76) completed 276 scenarios. The CW cohort demonstrated superior initial success rates (92.7% vs. 80.6%, p = 0.008). Battery exchanges (in normal and dim light, within carry bag) were completed twice as quickly for CW users ( p ≤ 0.001). Although controller exchange success rates were comparable, the duration to success and pump-off times were doubled for the HM3 cohort ( p ≤ 0.005). During the “connection to AC power” scenario, HM3 subjects experienced higher complexity, as the CW cohort achieved 5× lower duration to success and 3× higher initial success rates ( p ≤ 0.001). Survey responses favored CW cable lengths (92.9% vs. 69.0%, p = 0.001). This study highlights the advantages of CW’s user-centered design, which may enhance QoL and safety for future LVAD patients.

1 April 2021 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Open access
RMRoxana Moayedifar
Roxana Moayedifar
SSSigrid Sandner
Sigrid Sandner
EKE. Kagerl
E. Kagerl
JRJulia Riebandt
Julia Riebandt
Dominik WiedemannDominik Wiedemann
Dominik Wiedemann
Daniel ZimpferDaniel Zimpfer
Daniel Zimpfer

6 August 2024 in Artificial Organs
Verified
Journal Article
Open access
GWGregor Widhalm
Gregor Widhalm
PAPhilipp Aigner
Philipp Aigner
BGBernhard Gruber
Bernhard Gruber
FMFrancesco Moscato
Francesco Moscato
RMRoxana Moayedifar
Roxana Moayedifar
Thomas SchlöglhoferThomas Schlöglhofer
Thomas Schlöglhofer
Background: Left ventricular assist device (LVAD) malposition has been linked to hemocompatibility‐related adverse events (HRAEs). This study aimed to identify preoperative anatomical landmarks and postoperative pump position, associated with HRAEs during LVAD support.Methods: Pre‐ and postoperative chest X‐ray measures (≤14 days pre‐implantation, first postoperative standing, 6, 12, 18, and 24 months post‐implantation) were analyzed for their association with HRAEs over 24 months in 33 HeartMate 3 (HM3) patients (15.2% female, age 66 (9.5) years).Results: HM3 patients with any HRAE showed significantly lower preoperative distances between left ventricle and thoracic outline (dLVT) (25.3 ± 10.2 mm vs. 40.3 ± 15.5 mm, p = 0.004). A ROC‐derived cutoff dLVT ≤ 29.2 mm provided 85.7% sensitivity and 72.2% specificity predicting any HRAE during HM3 support (76.2% (>29.2 mm) vs. 16.7% (≤29.2 mm) freedom from HRAE, p < 0.001) and significant differences in cardiothoracic ratio (0.58 ± 0.04 vs. 0.62 ± 0.04, p = 0.045). Postoperative X‐rays indicated lower pump depths in patients with ischemic strokes (9.1 ± 16.2 mm vs. 38.0 ± 18.5 mm, p = 0.007), reduced freedom from any neurological event (pump depth ≤ 28.7 mm: 45.5% vs. 94.1%, p = 0.004), and a significant correlation between pump depth and inflow cannula angle (r = 0.66, p < 0.001). Longitudinal changes were observed in heart‐pump width (F(4,60) = 5.61, p < 0.001).Conclusion: Preoperative X‐ray markers are associated with postoperative HRAE occurrence. Applying this knowledge in clinical practice may enhance risk stratification, guide therapy optimization, and improve HM3 recipient management.

28 November 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
HAHebe Al Asadi
Hebe Al Asadi
TATheodor Abart
Theodor Abart
CSCaroline Schwarz
Caroline Schwarz
RMRoxana Moayedifar
Roxana Moayedifar
ASAnne-Kristin Schaefer
Anne-Kristin Schaefer
Thomas SchlöglhoferThomas Schlöglhofer
Thomas Schlöglhofer
Background: Patients with a HeartMate 3 (HM3) left ventricular assist device (LVAD) typically receive anticoagulation and antiplatelet therapy. The HM3 has shown a marked reduction in hemocompatibility-related adverse events (HRAEs) like stroke, bleeding, and pump thrombosis. This study evaluated whether aspirin (ASA) response influences HRAE incidence and if ASA sensitivity changes over time in HM3 recipients. Methods: This single-center, cross-sectional study included 32 HM3 patients (age: 59.0 ± 10.0 years, 15.6% female). ASA sensitivity was assessed twice using the VerifyNow assay, with ASA resistance defined by ASA reactivity units (ARU) > 550. The primary endpoint was HRAE incidence in ASA responders vs. non-responders over two consecutive follow-ups; the secondary endpoint was temporal changes in ASA resistance. Results: At the first follow-up, 13 (40.6%) patients were ASA-resistant, and 8 (28.6%) were resistant at the second follow-up, without significant change (p = 0.22). ASA non-responders and responders had similar ASA doses and baseline characteristics. No significant difference in HRAE incidence was found between ASA non-responders and responders (0.0% vs. 15.8%, p = 0.14), and no additional HRAEs occurred during follow-up. Conclusions: ASA resistance varied considerably among HM3 patients without significant temporal changes, and the demonstrated excellent hemocompatibility supports recent evidence that ASA may have a limited role in the antithrombotic regimen for HM3 recipients.

2 September 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
RMRoxana Moayedifar
Roxana Moayedifar
MCMuhammed Ilkay Celik
Muhammed Ilkay Celik
BKBarbara Karner
Barbara Karner
ASAnne-Kristin Schaefer
Anne-Kristin Schaefer
HAHebe Al Asadi
Hebe Al Asadi
Thomas SchlöglhoferThomas Schlöglhofer
Thomas Schlöglhofer
Background/Objectives: Preoperative hypoalbuminemia is a known risk factor for adverse outcomes in cardiac surgery, but its role in patients undergoing HeartMate 3 (HM3) left ventricular assist device (LVAD) implantation is unclear. This study evaluated the association between albumin levels and postoperative outcomes, aiming to define a clinically meaningful cut-off for risk stratification. Methods: We retrospectively analyzed 205 adult patients who underwent HM3 implantation at a single center from June 2014 to December 2023. Receiver operating characteristic (ROC) analysis identified an optimal pre-implant albumin cut-off of <32 g/L. This threshold, derived using the maximal Youden Index, provided a sensitivity of 52.1%, specificity of 71.6%, and an AUC of 0.64 (95% CI 0.56–0.71), with internal bootstrapping validation confirming model stability, and calibration demonstrating good agreement between predicted and observed outcomes. Kaplan–Meier analysis assessed freedom from hemocompatibility-related adverse events (HRAEs) and survival. Cox proportional hazards models evaluated albumin and other variables as independent risk factors for HRAEs. Results: Patients with pre-implant albumin <32 g/L had higher rates of HRAEs, including stroke (24.9% vs. 8.4%, p = 0.004) and bleeding (38.1% vs. 23.2%, p = 0.012). Freedom from HRAEs was significantly lower in the hypoalbuminemia group (45.2% vs. 69.8%, p < 0.001) and competing risk-adjusted cumulative incidence for HRAE was higher, but did not reach statistical significance (p = 0.11), one-year HRAE-free survival was also reduced (68.5% vs. 85.7%, p = 0.03). In multivariable analysis, low albumin (HR 0.56, 95% CI 0.33–0.93, p = 0.026) and temporary right ventricular assist device (RVAD) support (HR 3.32, 95% CI 2.05–5.39, p < 0.001) were independent predictors of HRAEs. Conclusions: Low preoperative albumin is independently associated with increased HRAEs and reduced one-year survival after HM3 implantation. Compared with the traditional 35 g/L threshold, the ROC-derived 32 g/L cut-off offered superior balance between sensitivity and specificity, underscoring its clinical utility. Albumin may serve as a simple, pragmatic, and cost-effective biomarker for preoperative risk assessment and optimization.